2017年

December 19, 2017: Consolidation of Group Production Functions (Absorption-type Demerger and Absorption-type Merger among the Wholly Owned Subsidiaries of the Company)
November 22, 2017: Notice on Production and Marketing License Agreement with Vietnamese Pharmaceutical Company
November 6, 2017: Supplementary information (Nov 6, 2017)
November 6, 2017: Summary of Consolidated Financial Results(For the Second Quarter Ended September 30, 2017)　[Japanese Standard]
September 28, 2017: Establishment of a Subsidiary
July 31, 2017: Summary of Consolidated Financial Results (For the first Quarter Ended Jun 30,2017)［Japanese Standard］
July 31, 2017: Consolidated Financial Results (For the first Quarter Ended Jun 30,2017)- Supplementary Information
May 11, 2017: Summary of Consolidated Financial Results
May 11, 2017: Consolidation of Group Production Functions
April 11, 2017: Kyorin acquired licenses from Merck & Co., Inc., Kenilworth, N.J., U.S.A. for Investigational Therapy for Overactive Bladder (Code:KRP-114V) in Asia
February 22, 2017: Change of Representative Director and President at ActivX Biosciences, Inc.
February 22, 2017: Establishment of a Representative Office in the Republic of Indonesia
February 3, 2017: Summary of Consolidated Financial Results (For the third Quarter Ended Dec 31,2016)［Japanese Standard］
February 3, 2017: Revision of Consolidated Financial Forecasts
February 3, 2017: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2017
January 11, 2017: Conclusion of Agreement on Business Alliance for Sale of Hand-Sanitizers